Can Diagnostics, Cell Therapy and Licensing Deals Reshape the Outlook for Rhythm (ASX:RHY), Arovella (ASX:ALA) and Argent BioPharma (ASX:RGT)?

Sonal Goyal

03 November 2026 10:38 PM AEDT

Can Diagnostics, Cell Therapy and Licensing Deals Reshape the Outlook for Rhythm (ASX:RHY), Arovella (ASX:ALA) and Argent BioPharma (ASX:RGT)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Rhythm Biosciences said its ColoSTAT test can now be ordered directly from GP practice software.
Arovella dosed its first patient in a phase 1 trial of its ALA-101 cell therapy.
Argent BioPharma granted a 10-year exclusive global licence for four cannabis genotypes.
Argent will receive a 15 per cent Royalty on profits from the licensed genetics.

Rhythm Biosciences Ltd (ASX:RHY), Arovella Therapeutics Limited (ASX:ALA) and Argent BioPharma Ltd (ASX:RGT) released updates on 27 October 2026. The reports cover colorectal and lung cancer testing in Australia and internationally, the first patient dosed in a clinical trial of an allogeneic cell therapy and a licensing agreement for legacy cannabis assets.

Latest Developments

Rhythm reported that its ColoSTAT colorectal test can now be ordered through MedicalDirector practice software, live since 1 August 2026. The company said its 4Cyte Pathology blood collection network has passed 100 sites in the eastern states, and that ColoSTAT has been accepted into the Therapeutic Goods Administration's in-house diagnostic database. An independent health economic study has been completed to support a potential Medicare reimbursement application, and technology transfer to an NHS England laboratory has been completed. Its geneType lung cancer risk test identified 42 per cent more cases eligible for screening than current Australian criteria.

Arovella said it had dosed the first patient in the SAPPHIRE phase 1 study of ALA-101, an off-the-shelf CD19-directed cell therapy. The open-label, dose-escalation trial is testing safety, tolerability and early activity in patients with relapsed or refractory B-cell cancers. The patient was treated at The Alfred, and the company's acting chief executive described the dosing as a key milestone.

Argent BioPharma entered a 10-year exclusive worldwide licence with Thai Phytomed International for four proprietary cannabis genotypes. Argent retains ownership of the genetics, while the licensee funds commercialisation and obtains approvals. Argent will receive a 15 per cent royalty on profits, including qualifying sublicensing, and the agreement supports its focus on pharmaceutical and anti-inflammatory development.

Sector Context

Diagnostics and therapeutics in Australia face reimbursement pathways that differ by product and market, and companies often pursue health economic evidence before seeking public funding. Early-stage cell therapy programs depend on clinical data and Manufacturing progress, while licensing income from legacy Assets can help fund core research.

The healthcare updates share a common theme of moving from development into commercial or clinical stages. Rhythm's focus is on getting its tests into clinical pathways and funding systems, Arovella's is on generating early clinical data, and Argent's is on monetising legacy assets while focusing its internal resources on pharmaceutical development. Each path involves regulatory, reimbursement or clinical milestones that take time, and results often arrive in stages rather than as a single outcome.

Risks to Consider

Clinical trials can change or stop, and early dosing does not confirm safety or efficacy. Rhythm's reimbursement pathways in Australia and the United States remain under review, and uptake of new tests depends on clinician adoption. Argent's royalty depends on its licensee's commercial success, which is outside its control. Rhythm's board has also changed recently, with Sue MacLeman appointed interim chair.

What to Watch Next

Investors may follow Rhythm's progress toward a Medicare application and the outcome of its US reimbursement review, Arovella's early safety data from the SAPPHIRE study, and Argent's royalty reporting as the licensee starts commercial activity.

Final Word

The three updates reflect health businesses at different stages, from diagnostic commercialisation to early clinical development and licensing of legacy assets. Upcoming trial, reimbursement and licensing disclosures will show how each program progresses, and readers may consult those releases for further detail.

FAQs

Q: How can doctors now access ColoSTAT?

A: Rhythm said GPs using MedicalDirector software can order ColoSTAT directly from their practice software, which has been live since 1 August 2026.

Q: What trial did Arovella start?

A: Arovella dosed the first patient in the SAPPHIRE phase 1 study of ALA-101, an allogeneic CD19-directed cell therapy for relapsed or refractory B-cell cancers.

Q: What royalty will Argent receive?

A: Argent will receive a 15 per cent royalty on profits from commercialising the licensed genetics, including qualifying sublicensing activity.

Q: How long does Argent's licence run?

A: The licence has an initial term of 10 years and may be renewed for a further 10 years on the same terms.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.